Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies: Research report

Journal of the Peripheral Nervous System

Volumn 13, Issue 4, 2008, Pages 283-288

  Penza, Paola ^a   Campanella, Angela ^a   Martini, Alfredo ^a   Melli, Giorgia ^a   Lombardi, Raffaella ^a   Camozzi, Francesca ^a   Devigili, Grazia ^b   Lauria, Giuseppe ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Buprenorphine; Nerve conduction studies; Neuropathic pain; Opioids; Pain relief; Painful neuropathy; Peripheral neuropathies; Treatment

Indexed keywords

BUPRENORPHINE; CARBAMAZEPINE; DULOXETINE; GABAPENTIN; METOCLOPRAMIDE; PREGABALIN; TRAMADOL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERALGESIA; HYPOTENSION; MALE; NAUSEA; NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; URINE RETENTION; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; TIME;

EID: 58449114941     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00194.x     Document Type: Article

References (25)

1. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P (2006). EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13 : 1153 1169.
2. Baron R (2006). Mechanisms of disease: neuropathic pain - a clinical perspective. Nat Clin Pract Neurol 2 : 95 106.
3. Bohme K (2002). Buprenorphine in a transdermal therapeutic system - a new option. Clin Rheumatol 21 : S13 S16.
4. Budd K (2003). Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl 133 : 9 14 discussion 23 14.
5. Carver A, Foley K (2001). Facts and an open mind should guide clinical practice. Curr Neurol Neurosci Rep 1 : 97 98.
6. Christoph T, Kogel B, Schiene K, Meen M, De Vry J, Friderichs E (2005). Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507 : 87 98.
7. Cruccu G (2007). Treatment of painful neuropathy. Curr Opin Neurol 20 : 531 535.
8. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2005). Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94 : 825 834.
9. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96 : 627 632.
10. Eisenberg E, McNicol ED, Carr DB (2005). Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 293 : 3043 3052.
11. England JD, Gould HJ III. (2002). Neuropathic pain. Adv Neurol 88 : 147 157.
12. Evans HC, Easthope SE (2003). Transdermal buprenorphine. Drugs 63 : 1999 2010 discussion 2011 1992.
13. Farrar JT, Young JP Jr., LaMoreaux L, Werth JL, Poole RM (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 : 149 158.
14. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH (2005). Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118 : 289 305.
15. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL (2005). Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 : 1324 1334.
16. Griessinger N, Sittl R, Likar R (2005). Transdermal buprenorphine in clinical practice - a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 21 : 1147 1156.
17. Hanna M, O'Brien C, Wilson MC (2008). Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 12 : 804 813.
18. Hans G (2007). Buprenorphine - a review of its role in neuropathic pain. J Opioid Manag 3 : 195 206.
19. Hansson PT, Dickenson AH (2005). Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain 113 : 251 254.
20. Kalso E, Edwards JE, Moore RA, McQuay HJ (2004). Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112 : 372 380.
21. Leander JD (1988). Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol 151 : 457 461.
22. Martucci C, Panerai AE, Sacerdote P (2004). Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 110 : 385 392.
23. Simonnet G (2005). Opioids: from analgesia to anti-hyperalgesia? Pain 118 : 8 9.
24. Sorge J, Sittl R (2004). Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 26 : 1808 1820.
25. Yaksh TL (1981). Spinal opiate analgesia: characteristics and principles of action. Pain 11 : 293 346.